Oligomerix is a biotechnology company based in New York, NY, dedicated to developing innovative therapeutics for neurodegenerative diseases characterized by abnormal tau protein, including rare tauopathies and Alzheimer's disease.
The company's lead candidate is a small molecule inhibitor of tau self-association, targeting the early stages of tau aggregation and its progression. Oligomerix's platform also includes a series of second-generation compounds, offering potential breakthroughs in the treatment of these debilitating conditions.
Generated from the website